We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Brazilian government has withdrawn its threat to compulsorily
licence Abbott Laboratories' Kaletra HIV/AIDS therapy, after the US firm agreed
to phase in a significant price reduction. Brazil had previously threatened
to break the patent unless Abbott reduced the price from US$1.17 to US$0.68
per dose.
According to reports in the UK media, Germany's Merck KGaA has now joined
Indian generics major Ranbaxy in opting to settle claims relating to a government
investigation into alleged price-fixing for generics supplied to the UK's National
Health Service (NHS).
Novartis, a major international manufacturer of pharmaceuticals and nutritional
products, has been identified as the company considering reopening the former
Slim-Fast plant.
PRB Pharmaceuticals and Lee's Pharmaceuticals announced today that Vietnam's
Department of Animal Health will begin testing an animal version of VIRA 38
on their poultry flocks as part of a multi-national, avian influenza research
collaboration.
Panacea Pharmaceuticals, a company focused on developing therapeutic and diagnostic
products for cancer, announced today that it has closed its Series C Private
Placement raising approximately $7 million.
VioQuest Pharmaceuticals, a biopharmaceutical company focused on acquiring,
developing and commercializing novel compounds with broad therapeutic applications,
entered into a definitive merger agreement to acquire Greenwich Therapeutics,
which owns exclusive license rights to two anti-cancer agents -- sodium stibogluconate
(SSG) and triciribine (TCN-P).
PTC Therapeutics (PTC), a biopharmaceutical company focused on the discovery,
development, and commercialization of small-molecule drugs targeting post-transcriptional
control mechanisms, today announced that PTC124 has been granted orphan drug
status for the treatment of Duchenne muscular dystrophy (DMD) and cystic fibrosis
(CF) by the Committee for Orphan Medicinal Products (COMP) of the European Medicines
Agency (EMEA).